Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLOD2 | O00469 | 3/20 | 0.61 |
| ▸ | PLOD3 | O60568 | 2/20 | 0.61 |
| ▸ | PLOD1 | Q02809 | 2/20 | 0.61 |
| ▸ | SMARCA2 | P51531 | 5/20 | 0.43 |
| ▸ | SMARCA4 | P51532 | 4/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25334034 | 0.81 | PLOD2 (0.61) | PLOD2PLOD3PLOD1SMARCA2SMARCA4 | |
| SCHEMBL7220421 | 0.79 | TAS1R3 (0.49) | PLOD2PLOD3PLOD1SMARCA2SMARCA4 | |
| SCHEMBL30866516 | 0.76 | GSK3B (0.48) | SMARCA2SMARCA4TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1924749 | 0.76 | PLOD2 (1.00) | PLOD2PLOD3PLOD1MEN1KMT2A | |
| SCHEMBL4101750 | 0.76 | GSK3B (0.48) | SMARCA2SMARCA4TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL8099539 | 0.76 | PLOD2 (0.56) | PLOD2PLOD3PLOD1 | |
| SCHEMBL29446533 | 0.76 | KMT2A (0.47) | SMARCA2SMARCA4TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL17336750 | 0.76 | KMT2A (0.47) | SMARCA2SMARCA4TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1349410 | 0.76 | PLOD2 (0.59) | PLOD2PLOD3PLOD1MEN1KMT2A | |
| SCHEMBL15907862 | 0.75 | PLOD2 (0.49) | PLOD2PLOD3PLOD1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722709-B2 | Mineralocorticoid receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-13 | — | — | US | disclosed |
| US-8722709-B2 | Mineralocorticoid receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-13 | — | — | US | disclosed |
| US-8722709-B2 | Mineralocorticoid receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-13 | — | — | US | disclosed |
| EP-2638012-A1 | PYRIDYL UREAS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2013-09-18 | — | — | EP | disclosed |
| US-20120289551-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2012-11-15 | — | — | US | disclosed |
| US-20120289551-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2012-11-15 | — | — | US | disclosed |
| US-20120289551-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2012-11-15 | — | — | US | disclosed |
| WO-2012064631-A1 | PYRIDYL UREAS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012064631-A1 | PYRIDYL UREAS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289551-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | NR3C2, MC2R, AVPR2 | PLOD2 4609/4885PLOD3 3461/4885PLOD1 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.